Risk factors for disease severity and increased medical resource utilization in respiratory syncytial virus (+) hospitalized children: A descriptive study conducted in four Belgian hospitals.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
08
2021
accepted:
02
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
We aimed to provide regional data on clinical symptoms, medical resource utilization (MRU), and risk factors for increased MRU in hospitalized respiratory syncytial virus (RSV)-infected Belgian pediatric population. This prospective, multicenter study enrolled RSV (+) hospitalized children (aged ≤5y) during the 2013-2015 RSV seasons. RSV was diagnosed within 24h of hospitalization. Disease severity of RSV (+) patients was assessed until discharge or up to maximum six days using a Physical Examination Score (PES) and a derived score based on ability to feed, dyspnea and respiratory effort (PES3). MRU (concomitant medications, length of hospitalization [LOH], and oxygen supplementation) was evaluated. Kaplan-Meier survival analysis was performed to compare MRU by age and presence of risk factors for severe disease. Association between baseline covariates and MRU was analyzed using Cox regression models. In total, 75 children were included, Median (range) age was 4 (0-41) months, risk factors were present in 18.7%, and early hospitalization (≤3 days of symptom onset) was observed in 57.3% of patients. Cough (100%), feeding problems (82.2%), nasal discharge (87.8%), and rales and rhonchi (82.2%) were frequently observed. Median (range) LOH and oxygen supplementation was 5 (2-7) and 3 (1-7) days. Oxygen supplementation, bronchodilators, and antibiotics were administered to 58.7%, 64.0%, and 41.3% of the patients, respectively. Age <3 months and baseline total PES3 score were associated with probability and the duration of receiving oxygen supplementation. LOH was not associated with any covariate. RSV is associated with high disease burden and MRU in hospitalized children. Oxygen supplementation but not length of hospitalization was associated with very young age and the PES3 score. These results warrant further assessment of the PES3 score as a predictor for the probability of receiving and length of oxygen supplementation in RSV hospitalized children. NCT02133092.
Sections du résumé
BACKGROUND
We aimed to provide regional data on clinical symptoms, medical resource utilization (MRU), and risk factors for increased MRU in hospitalized respiratory syncytial virus (RSV)-infected Belgian pediatric population.
METHODS
This prospective, multicenter study enrolled RSV (+) hospitalized children (aged ≤5y) during the 2013-2015 RSV seasons. RSV was diagnosed within 24h of hospitalization. Disease severity of RSV (+) patients was assessed until discharge or up to maximum six days using a Physical Examination Score (PES) and a derived score based on ability to feed, dyspnea and respiratory effort (PES3). MRU (concomitant medications, length of hospitalization [LOH], and oxygen supplementation) was evaluated. Kaplan-Meier survival analysis was performed to compare MRU by age and presence of risk factors for severe disease. Association between baseline covariates and MRU was analyzed using Cox regression models.
RESULTS
In total, 75 children were included, Median (range) age was 4 (0-41) months, risk factors were present in 18.7%, and early hospitalization (≤3 days of symptom onset) was observed in 57.3% of patients. Cough (100%), feeding problems (82.2%), nasal discharge (87.8%), and rales and rhonchi (82.2%) were frequently observed. Median (range) LOH and oxygen supplementation was 5 (2-7) and 3 (1-7) days. Oxygen supplementation, bronchodilators, and antibiotics were administered to 58.7%, 64.0%, and 41.3% of the patients, respectively. Age <3 months and baseline total PES3 score were associated with probability and the duration of receiving oxygen supplementation. LOH was not associated with any covariate.
CONCLUSION
RSV is associated with high disease burden and MRU in hospitalized children. Oxygen supplementation but not length of hospitalization was associated with very young age and the PES3 score. These results warrant further assessment of the PES3 score as a predictor for the probability of receiving and length of oxygen supplementation in RSV hospitalized children.
REGISTRATION
NCT02133092.
Identifiants
pubmed: 35666728
doi: 10.1371/journal.pone.0268532
pii: PONE-D-21-25349
pmc: PMC9170098
doi:
Banques de données
ClinicalTrials.gov
['NCT02133092']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0268532Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: YV, RF, JB, and GI are employees of Janssen Pharmaceutica NV and may own stock in Johnson & Johnson. MP, AR, EK, FV, KS, MR, AV, WL, and KG have no conflict of interest.
Références
CJEM. 2003 Jul;5(4):239-44
pubmed: 17472765
Medicine (Baltimore). 2018 Jul;97(29):e11491
pubmed: 30024527
Arch Pediatr Adolesc Med. 2002 Apr;156(4):322-4
pubmed: 11929363
Vaccine. 2018 Oct 29;36(45):6591-6593
pubmed: 30266485
Lancet Respir Med. 2018 Jan;6(1):65-74
pubmed: 28865676
Ann Clin Lab Sci. 2007 Winter;37(1):79-84
pubmed: 17311874
Paediatr Child Health. 1999 Apr;4(3):195-9
pubmed: 20212965
Arch Pediatr Adolesc Med. 2004 Jun;158(6):527-30
pubmed: 15184214
Pediatr Pulmonol. 2013 Aug;48(8):797-803
pubmed: 22949369
Int J Pediatr. 2017;2017:3169098
pubmed: 29181038
Klin Padiatr. 2002 Nov-Dec;214(6):334-42
pubmed: 12424681
Euro Surveill. 2018 Feb;23(5):
pubmed: 29409569
J Clin Virol. 2018 Jul;104:77-82
pubmed: 29763837
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
Infect Control Hosp Epidemiol. 2009 Dec;30(12):1211-7
pubmed: 19852666
Infection. 2019 Apr;47(2):201-207
pubmed: 30132249
Acta Clin Belg. 2019 Aug;74(4):229-235
pubmed: 30029583
Pediatr Allergy Immunol. 2006 Aug;17(5):376-81
pubmed: 16846457
Klin Padiatr. 2004 Jan-Feb;216(1):7-15
pubmed: 14747964
Clin Infect Dis. 2021 Jun 15;72(12):2071-2075
pubmed: 32986818
Euro Surveill. 2018 Jan;23(3):
pubmed: 29386093
Pediatrics. 2008 Mar;121(3):470-5
pubmed: 18310194
Euro Surveill. 2020 Oct;25(39):
pubmed: 33006303
Thorax. 2006 Jul;61(7):611-5
pubmed: 16537670
Pediatr Infect Dis J. 2018 Nov;37(11):1077-1081
pubmed: 29601448
Pediatr Qual Saf. 2019 Aug 30;4(5):e211
pubmed: 31745514
PLoS One. 2018 Nov 15;13(11):e0206474
pubmed: 30439987
PLoS One. 2016 Sep 30;11(9):e0163217
pubmed: 27690359
J Med Virol. 2005 Feb;75(2):282-9
pubmed: 15602730
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Clin Infect Dis. 2021 Jun 15;72(12):2199-2202
pubmed: 32986804
Lancet. 2020 Nov 21;396(10263):1633-1634
pubmed: 33228919
J Pediatric Infect Dis Soc. 2020 Nov 10;9(5):587-595
pubmed: 31868913
Influenza Other Respir Viruses. 2017 Mar;11(2):122-129
pubmed: 28058797
Clin Infect Dis. 2021 Jan 27;72(2):319-322
pubmed: 33501967
J Hosp Infect. 2017 Aug;96(4):360-365
pubmed: 28559125
Paediatr Respir Rev. 2004;5 Suppl A:S119-26
pubmed: 14980256
J Infect Dis. 2011 Oct 1;204(7):996-1002
pubmed: 21881113
Pediatr Qual Saf. 2017 Dec 01;2(6):e046
pubmed: 30229182
Eur J Pediatr. 2021 Jun;180(6):1969-1973
pubmed: 33517482
Arch Dis Child. 2004 Apr;89(4):363-7
pubmed: 15033849
Antimicrob Agents Chemother. 2004 Aug;48(8):2787-92
pubmed: 15273082
Expert Rev Anticancer Ther. 2019 Oct;19(10):835-846
pubmed: 31544541
Clin Infect Dis. 2012 Mar;54(6):810-7
pubmed: 22247121
BMJ Open. 2016 Jun 02;6(6):e009337
pubmed: 27256085
Epidemiol Infect. 2019 Jan;147:e246
pubmed: 31364578
J Clin Virol. 2017 Sep;94:72-78
pubmed: 28772168
Infect Dis Ther. 2016 Sep;5(3):271-98
pubmed: 27480325
Am J Respir Crit Care Med. 2010 Nov 15;182(10):1305-14
pubmed: 20622030